Kepler Capital Keeps Their Buy Rating on MaaT Pharma (MAAT)
Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on April 2 and set a price target of ...
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results
MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of ...
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to ...
Kepler Capital Remains a Buy on MaaT Pharma (MAAT)
Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on March 27 and set a price target of ...
pharmaphorum9d
MaaT microbiota drug shows survival advantage in GvHD
MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).
Investing.com India8d
MaaT Pharma announces FY24 results and €13m private placement
Investing.com -- MaaT Pharma has unveiled its financial results for fiscal year 2024 (FY24), reporting a revenue of €3.2m, a 44% increase from 2023. This surge in revenue is largely attributed to an ...
Finanznachrichten8d
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results
Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies (MET) dedicated to enhancing ...